PNE Wind Anleihe 2018(2023)

DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

Nachricht vom 03.01.2018 (www.4investors.de) -


DGAP-News: Evotec AG / Key word(s): Conference

EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
03.01.2018 / 11:42


The issuer is solely responsible for the content of this announcement.
Hamburg, Germany, 03 January 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at the 17th German Corporate Conference 2018 jointly hosted by UniCredit and Kepler Cheuvreux, Frankfurt, Germany, and will be attending the 36th Annual J.P. Morgan Healthcare Conference, San Francisco, USA, the Bankhaus Lampe German Equity Forum, London, UK, the BioCapital Europe 2018, Amsterdam, The Netherlands, and the 12th ODDO German Conference, Frankfurt, Germany.

36th Annual J.P. Morgan Healthcare Conference, San Francisco, USA

- Date: Monday, 08 January, until Thursday, 11 January 2018

- Venue: San Francisco, USA

17th German Corporate Conference 2018 jointly hosted by UniCredit and Kepler Cheuvreux, Frankfurt, Germany

- Date: Monday, 15 January 2018, 05.30 pm CET (04.30 pm GMT/11.30 am EST)

- Venue: Frankfurt, Germany
 

Bankhaus Lampe German Equity Forum, London, UK

- Date: Thursday, 01 February 2018

- Venue: London, UK

BioCapital Europe 2018, Amsterdam, The Netherlands

- Date: Tuesday, 06 February 2018

- Venue: Amsterdam, The Netherlands

 

12th ODDO German Conference, Frankfurt, Germany

- Date: Wednesday, 21 February 2018

- Venue: Frankfurt, Germany

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.

FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.












03.01.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
Evotec AG

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg


Germany
Phone:
+49 (0)40 560 81-0
Fax:
+49 (0)40 560 81-222
E-mail:
info@evotec.com
Internet:
www.evotec.com
ISIN:
DE0005664809
WKN:
566480
Indices:
TecDAX
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News
DGAP News Service




642653  03.01.2018 









Aktuelle Nachrichten aus der 4investors-Redaktion

24.04.2018 - sleepz: Zahlen verfehlen die Erwartungen
24.04.2018 - Beiersdorf holt Nestle-Managerin
24.04.2018 - Dialog Semiconductor Aktie: Eine Falle, oder ein Impuls?
24.04.2018 - Deutsche Industrie REIT: Zukauf in Ronnenberg
24.04.2018 - Deutsche Bank: Neues aus dem Management - Aktie mit Ausbruch?
24.04.2018 - QSC Aktie: Bodenbildung scheint gelungen, aber…
24.04.2018 - wallstreet:online AG: Kapitalerhöhung für ICO-Sparte im Anmarsch?
24.04.2018 - Deutsche Bank Aktie: Hier tut sich Wichtiges!
24.04.2018 - OHB: Neuer Ariane-Auftrag
24.04.2018 - Stemmer Imaging steigert Umsatz und Gewinn


Chartanalysen

24.04.2018 - Dialog Semiconductor Aktie: Eine Falle, oder ein Impuls?
24.04.2018 - QSC Aktie: Bodenbildung scheint gelungen, aber…
24.04.2018 - Deutsche Bank Aktie: Hier tut sich Wichtiges!
24.04.2018 - Deutsche Telekom Aktie: Nimmt der Aktienkurs Fahrt auf?
24.04.2018 - E.On Aktie: Hier könnte etwas passieren!
24.04.2018 - Bitcoin Group Aktie: Das sieht interessant aus!
24.04.2018 - Formycon Aktie: Auffällige Entwicklungen!
24.04.2018 - Commerzbank Aktie: Achtung, sehr interessante News!
23.04.2018 - Bitcoin Group Aktie: Hier geht etwas, wenn…
23.04.2018 - H+R Aktie: Raus aus den Sorgen?


Analystenschätzungen

24.04.2018 - Mensch und Maschine: Kaufempfehlung für die Aktie
24.04.2018 - Munich Re: Neues Kursziel im herausfordernden Marktumfeld
24.04.2018 - Alphabet: Erwartungen übertroffen – Kursziel sinkt
24.04.2018 - Software AG: Ein leichtes Minus
24.04.2018 - Metro: Heftige Abstufung
24.04.2018 - ProSiebenSat.1: Eine gewisse Zurückhaltung
24.04.2018 - FMC: Doppelte Hochstufung der Aktie
24.04.2018 - Volkswagen: Gibt es eine positive Überraschung?
23.04.2018 - Mutares: Kaufen nach der IPO-Ankündigung
23.04.2018 - UBS Group: Zu hohes Minus


Kolumnen

24.04.2018 - ifo-Geschäftsklima: Unternehmensstimmung kühlt sich im April weiter ab - Nord LB Kolumne
24.04.2018 - Im Euroraum stabilisiert sich die Unternehmensstimmung - Commerzbank Kolumne
24.04.2018 - Commerzbank Aktie: Trendverstärkung voraus - UBS Kolumne
24.04.2018 - DAX: Reversal zu Wochenbeginn stimmt positiv - UBS Kolumne
24.04.2018 - Was ist schon normal? – Sarasin Kolumne
24.04.2018 - DAX: Dreieck spitzt sich zu - 12.651 im Fokus - Donner + Reuschel Kolumne
23.04.2018 - DAX stabil zum Wochenstart: „Verflixte Dreieckskiste“ - Donner + Reuschel Kolumne
23.04.2018 - Microsoft Aktie: Top-Bildung möglich - UBS Kolumne
23.04.2018 - DAX: Patt-Situation zwischen Bullen und Bären - UBS Kolumne
20.04.2018 - Schweizer Franken: Der ehemalige Mindestwechselkurs lässt grüßen - VP Bank Kolumne

All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR